DK1192134T3 - Fremgangsmåde til fremstilling af (R)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinmethanol - Google Patents

Fremgangsmåde til fremstilling af (R)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinmethanol

Info

Publication number
DK1192134T3
DK1192134T3 DK99911318T DK99911318T DK1192134T3 DK 1192134 T3 DK1192134 T3 DK 1192134T3 DK 99911318 T DK99911318 T DK 99911318T DK 99911318 T DK99911318 T DK 99911318T DK 1192134 T3 DK1192134 T3 DK 1192134T3
Authority
DK
Denmark
Prior art keywords
dimethoxyphenyl
fluorophenyl
ethyl
preparation
piperidine methanol
Prior art date
Application number
DK99911318T
Other languages
English (en)
Inventor
Alan G Bina
Edward D Daugs
Jonathan C Evans
Hans-Wolfram Flemming
Gerard Guillamot
Robert A Hawtorne
Thomas H E Hilpert
James E Hitt
Frederick M Laskovics
Sharon K Minish
Thomas T Ortyl
Lian G Rajewski
Marvin J Sack
Paul F Skultety
Sandra K Stoltz-Dunn
Alonzo L Tigner
Ian A Tomlinson
Chi-Hsin R King
Johannes N Koek
John M Lefler
Alexey L Margolin
Original Assignee
Aventis Pharma Inc
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc, Hoechst Marion Roussel De Gmbh filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of DK1192134T3 publication Critical patent/DK1192134T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK99911318T 1998-03-13 1999-03-11 Fremgangsmåde til fremstilling af (R)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinmethanol DK1192134T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4225198A 1998-03-13 1998-03-13
US25071899A 1999-02-16 1999-02-16
PCT/US1999/005332 WO1999046245A2 (en) 1998-03-13 1999-03-11 PROCESSES FOR THE PREPARATION OF (R)-α- (2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL

Publications (1)

Publication Number Publication Date
DK1192134T3 true DK1192134T3 (da) 2007-11-26

Family

ID=26719032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99911318T DK1192134T3 (da) 1998-03-13 1999-03-11 Fremgangsmåde til fremstilling af (R)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinmethanol

Country Status (25)

Country Link
EP (3) EP1192134B1 (da)
JP (2) JP4511723B2 (da)
KR (7) KR100591640B1 (da)
CN (1) CN100436415C (da)
AR (1) AR015540A1 (da)
AT (1) ATE373639T1 (da)
AU (1) AU755436B2 (da)
BR (1) BR9909260A (da)
CA (1) CA2322501C (da)
CY (1) CY1107104T1 (da)
DE (1) DE69937162T2 (da)
DK (1) DK1192134T3 (da)
DZ (1) DZ2742A1 (da)
EG (1) EG24052A (da)
ES (1) ES2294838T3 (da)
HK (1) HK1042484B (da)
HU (1) HUP0400889A3 (da)
IL (3) IL138307A0 (da)
MA (1) MA25515A1 (da)
NO (1) NO317981B1 (da)
NZ (1) NZ506807A (da)
PT (1) PT1192134E (da)
TN (1) TNSN99035A1 (da)
TW (1) TWI249526B (da)
WO (1) WO1999046245A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
TWI428151B (zh) * 2006-12-07 2014-03-01 Daiichi Sankyo Co Ltd 含有甘露醇或乳糖之固形製劑
US8964338B2 (en) 2012-01-11 2015-02-24 Emerson Climate Technologies, Inc. System and method for compressor motor protection
AU2014229103B2 (en) 2013-03-15 2016-12-08 Emerson Electric Co. HVAC system remote monitoring and diagnosis
CN112358398A (zh) * 2020-11-19 2021-02-12 山东新华制药股份有限公司 D-(+)-二对甲苯甲酰酒石酸的回收制备方法
CN116082705B (zh) * 2022-12-05 2023-09-12 苏州易昇光学材料股份有限公司 一种抗黄变自修复凝胶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260623A (en) * 1979-11-26 1981-04-07 Warner-Lambert Company Hexahydro-1-arylspiro(3H-oxazolo(3,4-A)pyridine-3,4'-piperidene) antidepressants, pharmaceutical compositions thereof and method of use thereof
ZA864772B (en) * 1985-07-02 1987-02-25 Merrell Dow Pharma Novel chemical compounds
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
JP2869512B2 (ja) * 1990-06-01 1999-03-10 メレルダウファーマスーティカルズ インコーポレイテッド （＋）―α―（２，３―ジメトキシフェニル）―１―［２―（４―フルオロフェニル）エチル］―４―ピペリジンメタノール
AU650031B2 (en) * 1990-06-07 1994-06-09 Aventisub Ii Inc. 1-Piperidinyl alkanoylarylsulfonamide derivatives
US5477029A (en) * 1994-01-28 1995-12-19 Skutt Ceramic Products, Inc. Kiln with hinged control panel
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Also Published As

Publication number Publication date
IL138307A0 (en) 2001-10-31
CN100436415C (zh) 2008-11-26
AU2998899A (en) 1999-09-27
KR20060002037A (ko) 2006-01-06
HK1042484A1 (en) 2002-08-16
EP1734037A2 (en) 2006-12-20
MA25515A1 (fr) 2002-10-01
JP2002506059A (ja) 2002-02-26
JP4511723B2 (ja) 2010-07-28
KR20060002034A (ko) 2006-01-06
ES2294838T3 (es) 2008-04-01
EP1736469A2 (en) 2006-12-27
PT1192134E (pt) 2007-11-13
KR20060002035A (ko) 2006-01-06
CN1300280A (zh) 2001-06-20
IL175983A0 (en) 2006-10-05
NO20004545D0 (no) 2000-09-12
CY1107104T1 (el) 2012-01-25
AU755436B2 (en) 2002-12-12
NO20004545L (no) 2000-11-13
KR20010041819A (ko) 2001-05-25
DE69937162D1 (de) 2007-10-31
TWI249526B (en) 2006-02-21
ATE373639T1 (de) 2007-10-15
NO317981B1 (no) 2005-01-17
CA2322501C (en) 2006-05-09
KR100591643B1 (ko) 2006-06-20
KR100586327B1 (ko) 2006-06-08
EP1734037A3 (en) 2010-06-16
KR100591641B1 (ko) 2006-06-20
KR20060002039A (ko) 2006-01-06
NZ506807A (en) 2003-03-28
KR100591642B1 (ko) 2006-06-20
EP1192134B1 (en) 2007-09-19
HK1042484B (zh) 2008-05-02
WO1999046245A2 (en) 1999-09-16
DZ2742A1 (fr) 2003-09-08
KR100591640B1 (ko) 2006-06-20
JP2010143925A (ja) 2010-07-01
KR20060002036A (ko) 2006-01-06
HUP0400889A3 (en) 2010-08-30
WO1999046245A3 (en) 1999-10-21
CA2322501A1 (en) 1999-09-16
AR015540A1 (es) 2001-05-02
IL138307A (en) 2006-09-05
KR100586328B1 (ko) 2006-06-08
HUP0400889A2 (hu) 2004-08-30
TNSN99035A1 (fr) 2005-11-10
EP1192134A2 (en) 2002-04-03
KR20060002038A (ko) 2006-01-06
BR9909260A (pt) 2000-11-21
DE69937162T2 (de) 2008-06-12
EG24052A (en) 2008-04-13
KR100591997B1 (ko) 2006-06-26
EP1736469A3 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
IL156461A0 (en) Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
NO970939D0 (no) Fremgangsmåte ved fremstilling av paroksetinhydrokloridanhydrat
NO20071888L (no) Fremgangsmate for a syntetisere 4-aminosubstituerte forbindelser
EE05531B1 (et) Tert-butl-(E)-(6-{2-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]vinl}(4R, 6S)-2,2-dimetl[1,3]dioksaan-4-l)atsetaadi valmistamismeetod
CY1107104T1 (el) Διαδικασια για την παρασκευη (r)-g(a)-(2,3-διμεθοξυφαινυλο)-1-(2-(4-φθοροφαινυλο)-αιθυλο)-4- πιπεριδινομεθανολη
DK0994091T3 (da) Fremgangsmåde til fremstilling methanol
DK1362040T3 (da) Fremgangsmåde til fremstilling af mesylater af piperidinderivater
DK1289527T3 (da) (+)-alfa.(2,3-dimethoxyphenyl)-1-(2-(4-fluorphenyl)-ethyl)-4-piperodonmethanol eller dets prolægemiddel til behandling af demens eller kognitiv svækkelse
DK0828711T3 (da) Hidtil ukendt fremgangsmåde til fremstilling af ropivacainhydrochloridmonohydrat
DK0888114T3 (da) Anvendelse af (+)-alfa-(2,3-dimethoxyphenyl)-1-[2-(4-flourphenyl)-ethyl]-4-piperidinmethanol til behandling af depressive lidelser og bipolare lidelser
HK1006359A1 (en) Salts of ethyl 3-(2-(4-(4-(amino-imino-methyl)phenyl)-4-methyl-2, 5-dioxo -imidazoldin-1-yl)acetylamino)-3 -phenylpropionate
DK1049674T3 (da) Fremgangsmåde til fremstilling af (-) cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl) -piperidin
HK1061843A1 (en) Process for cis-1-(2-(4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronape ethyl) pyrrolidine
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
BR9809809B1 (pt) processo para a preparação de um composto (-)-trans-1-benzil-3-hidroximetil-4-(4-fluorofenil) piperidina, e, processo para a preparação de paroxetina.
DK1100796T3 (da) Fremgangsmåde til fremstilling af en ikke-krystallinsk anhydratform af paroxetinhydrochlorid
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-
AU2001297647A1 (en) Process for resolving racemic mixtures of piperidine derivatives
DK1209977T3 (da) Fremgangsmåde til bekæmpelse af svampe ved anvendelse af phenylhydrazin-derivater
DK1127876T3 (da) Fremgangsmåde til fremstilling af isoindolin
AU1398500A (en) Process for the production of paroxetine hydrochloride propan-2-ol solvate
EE200300204A (et) Meetod distamütsiini derivaadi valmistamiseks
SI1192134T1 (sl) Postopki za pripravo (R)-alfa-(2,3-dimetoksifenil)-1-2-(4-fluorofenil) etil)-4-piperidinmetanola
IS5523A (is) Aðferð til að framleiða ísóprópýl-metýl-[2-(3-n-própoxýfenoxý)-etýl]amín
AU6481799A (en) Process for the preparation of paroxetine hydrochloride